Head-To-Head Survey: Aethlon Medical (AEMD) and Its Rivals
Aethlon Medical (NASDAQ: AEMD) is one of 23 public companies in the “Analytical instruments” industry, but how does it contrast to its competitors? We will compare Aethlon Medical to related companies based on the strength of its analyst recommendations, institutional ownership, risk, profitability, earnings, dividends and valuation.
Insider & Institutional Ownership
6.9% of Aethlon Medical shares are owned by institutional investors. Comparatively, 59.0% of shares of all “Analytical instruments” companies are owned by institutional investors. 6.6% of Aethlon Medical shares are owned by insiders. Comparatively, 14.6% of shares of all “Analytical instruments” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
This is a breakdown of current ratings and price targets for Aethlon Medical and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Aethlon Medical Competitors||115||736||1089||51||2.54|
Aethlon Medical currently has a consensus price target of $3.00, suggesting a potential upside of 172.73%. As a group, “Analytical instruments” companies have a potential upside of 7.50%. Given Aethlon Medical’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Aethlon Medical is more favorable than its competitors.
Volatility & Risk
Aethlon Medical has a beta of 1.93, meaning that its share price is 93% more volatile than the S&P 500. Comparatively, Aethlon Medical’s competitors have a beta of 1.10, meaning that their average share price is 10% more volatile than the S&P 500.
Earnings and Valuation
This table compares Aethlon Medical and its competitors top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Aethlon Medical||$150,000.00||-$5.67 million||-2.39|
|Aethlon Medical Competitors||$1.08 billion||$109.59 million||25.19|
Aethlon Medical’s competitors have higher revenue and earnings than Aethlon Medical. Aethlon Medical is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
This table compares Aethlon Medical and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Aethlon Medical Competitors||-206.30%||-32.89%||-15.19%|
Aethlon Medical competitors beat Aethlon Medical on 8 of the 13 factors compared.
About Aethlon Medical
Aethlon Medical, Inc., a medical device company, focuses on creating devices that address unmet medical needs in health and biodefense worldwide. The company is developing Aethlon Hemopurifier, a clinical-stage therapeutic device that eliminates life-threatening viruses from the circulatory system of infected individuals. It is also involved in the development of exosomal biomarkers to diagnose and monitor life-threatening disease conditions, such as cancer and neurological disorders; and a therapeutic device to reduce the incidence of sepsis, a fatal bloodstream infection. The company was founded in 1991 and is based in San Diego, California.
Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with MarketBeat.com's FREE daily email newsletter.